Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Debt (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Non-Current Debt data on record, last reported at $608.6 million in Q3 2025.

  • For Q3 2025, Non-Current Debt rose 2.03% year-over-year to $608.6 million; the TTM value through Sep 2025 reached $608.6 million, up 2.03%, while the annual FY2024 figure was $601.6 million, 2.04% up from the prior year.
  • Non-Current Debt reached $608.6 million in Q3 2025 per AMPH's latest filing, roughly flat from $607.7 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $638.2 million in Q3 2023 and bottomed at $30.5 million in Q2 2021.
  • Average Non-Current Debt over 5 years is $341.9 million, with a median of $488.3 million recorded in 2023.
  • Peak YoY movement for Non-Current Debt: fell 11.19% in 2021, then surged 762.31% in 2023.
  • A 5-year view of Non-Current Debt shows it stood at $74.8 million in 2021, then decreased by 2.59% to $72.8 million in 2022, then surged by 709.43% to $589.6 million in 2023, then increased by 2.04% to $601.6 million in 2024, then grew by 1.16% to $608.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $608.6 million in Q3 2025, $607.7 million in Q2 2025, and $603.9 million in Q1 2025.